Navigation Links
CTI Reports Final Results from Cooperative Group and NCI-Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
Date:6/1/2013

CHICAGO and SEATTLE, June 1, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported on final results from a cooperative group and NCI-sponsored Phase 2 clinical trial of brostallicin in combination with cisplatin for the treatment of women with metastatic triple-negative breast cancer (mTNBC). Triple-negative breast cancer lacks progesterone and estrogen receptors and the HER2 biomarker that is present in most breast cancers, which makes standard therapy with hormone or targeted therapy ineffective. The rationale for the present study in TNBC is based on data the demonstrating that silencing of the breast cancer susceptibility gene(s) (BRCA) is associated with substantially enhanced sensitivity to brostallicin.  BRCA is silenced or mutated in most patients with TNBC. In this study of 48 patients with heavily pretreated mTNBC, the 3-month progression free survival (PFS) was 51 percent with 10 confirmed responses (one complete response and nine partial responses). Among the 25 patients who received a reduced brostallicin dose, the overall response rate (ORR) was 28 percent, with 3-month progression-free survival (PFS) of 61.5 percent and median overall survival (OS) of 11.8 months. The final data are being presented during a poster session at the 2013 American Society for Clinical Oncology (ASCO) Meeting being held May 31 to June 4, 2013 in Chicago, Illinois.

Abstract #1059:  Final clinical results and correlative data from the phase II trial of cisplatin (C) and the novel agent brostallicin (B) in patients with metastatic triple negative breast cancer (mTNBC). Poster session, Saturday, June 1, 1:15 to 5:00 p.m. CDT in S Hall A2.

About the Study

The study enrolled women with confirmed measurable metastatic disease and triple-negative subtype breast cancer. A total of 48 women were enrolled in the study and 47 were evaluable for efficacy. Approximately half of the patients had received between two and four prior chemotherapy regimens in the metastatic setting. The primary endpoint of the trial was 3-month PFS. Secondary endpoints included ORR, duration of response, 6-month PFS, OS and safety. In this study, patients received cisplatin on Day 1, brostallicin on Day 2, and GCSF or pegylated-GCSF on Day 3, with the cycle repeated every 21 days. The study was led by investigators at the Mayo Clinic in Florida. Key findings include:

  • As of this analysis, 10 of 47 evaluable patients achieved a confirmed tumor response. One patient had a complete response (CR) and nine patients had a partial response (PR),
  • 3-month PFS was 51 percent and 6-month PFS was 28 percent; median time to progression was 3.2 months, and
  • Adverse events were mostly hematologic (75 percent) and consistent with other treatments in this setting.

In an exploratory analysis, patients who received a reduced dose of brostallicin had an apparent increase in efficacy (ORR= 28 percent; 3-month PFS=61.5 percent; median OS=11.8 months) with a significant decrease in febrile neutropenia compared to cycle 1.

The authors concluded that in this study the combination of brostallicin and cisplatin was an active regimen in heavily pre-treated metastatic triple-negative breast cancer patients. A follow-up randomized Phase 2 trial using the reduced dosing regimen is in development.

The poster is available at www.celltherapeutics.com.

About Triple-Negative Breast Cancer

This term is used to describe breast cancers (usually invasive ductal carcinomas) whose cells lack estrogen and progesterone receptors, and do not express HER2. Breast cancers with these characteristics occur more often in younger women and African-American women. Triple-negative breast cancers are diagnosed at a later stage and spread more quickly than most other types of breast cancer. Because the tumor cells lack receptors, neither hormone therapy nor drugs that target HER2 are effective.1 Patients with TNBC may respond to chemotherapy but responses are generally short and no therapy has been shown to be effective in patients who have more than one relapse.2 About 10 to 20 percent of breast cancers are triple-negative.3

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has shown potent cancer killing activity, and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies, in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death.  More than 200 patients have been treated with brostallicin in single-agent and combination studies.

About Cell Therapeutics, Inc.

Cell Therapeutics (Nasdaq and MTA: CTIC) is a biopharmaceutical company committed to the development and commercialization of an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is headquartered in Seattle, WA. For additional information and to sign up for email alerts and get RSS feeds, please visit www.CellTherapeutics.com.

Safe Harbor Statement

This press release includes forward-looking statements that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with brostallicin in particular, including, without limitation, the potential failure of brostallicin to prove safe and effective for the treatment of women with metastatic triple-negative breast cancer, either alone or in combination with cisplatin, as determined by the U.S. Food and Drug Administration and/or the European Medicines Agency; that additional clinical trials of brostallicin may not occur as planned; CTI's ability to continue to raise capital as needed to fund its operations; and competitive factors, technological developments, costs of developing, producing and selling CTI's product candidates, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

References

  1. American Cancer Society. Available at http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-breast-cancer-types   Accessed May 2013. 
  2. Chacon, Renaldo;Constanzo Maria. "Triple-negative breast cancer." Breast Cancer Research. 12(suppl 2):S3 (2010). Available at http://breast-cancer-research.com/content/12/S2/S3. Accessed May 2013.
  3. Living Beyond Breast Cancer: Guide to Understanding Triple-Negative Breast Cancer 2nd Edition 2012. Available at http://www.lbbc.org/Understanding-Breast-Cancer/Guides-to-Understanding-Breast-Cancer/Guide-to-Understanding-Triple-Negative-Breast-Cancer. Accessed May 2013.

CTI Media and Investor Contacts:

Monique Greer
+1 206.272.4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
invest@ctiseattle.com

In Europe

CTI Life Sciences Limited, Milan Branch

Laura Villa
Elena Bellacicca

E: CTI_EUInvestors@CTI-Lifesciences.com
T: +39 02 89659700
F: +39 02 89659719
http://www.celltherapeutics.com/italiano


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Kinase Market Profiling - In House & Outsourced Trends 2015 Forecast in New Research Report at ReportsnReports.com
2. Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy
3. Vermillion Reports First Quarter 2013 Results
4. Dyadic International Reports First Quarter 2013 Financial Results
5. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
6. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
7. Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update
8. Vanda Pharmaceuticals Reports First Quarter 2013 Results
9. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
10. Regeneron Reports First Quarter 2013 Financial and Operating Results
11. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
Breaking Biology News(10 mins):